2. Novo Nordisk
Novo Nordisk is a biopharmaceutical company that specializes in the treatment of diabetes. This leading distributor of insulin as well as other anti-diabetic therapies is based in Denmark.
Income Statement: In the second quarter ending June 30, Novo Nordisk shrank by 10% on its top and bottom lines. However, full year earnings per share is expected to grow from $3.92 to $4.67 over the next 12 months.
Balance Sheet: The company has been successful in reducing its outstanding debt to just $168 million, or just 3% of total equity.
Stock Ratios: The company's 5-year annualized growth rate for sales of 12.8% exceeds the industry average contraction of 6.4% and S&P 500 growth reading of 2.6%.
Analyst Ratings: Our model rates Novo Nordisk at a grade of A-Plus, or strong buy. Aside from our rating, six analysts recommend holding the stock.
1. Monro Muffler Brake
Company Profile: Monro Muffler Brake fixes brakes, mufflers, and complete other automotive repair work in its network of more than 700 stores. The company is based in Rochester, New York.
Income Statement: In the fiscal first quarter ending June 26, Monro Muffler Brake’s top line revenue jumped by 23.6% to $158 million over the year ago quarter. Over the same period, net income leapt by 40.4% to $13.2 million. Full-year earnings per share are expected to grow from $2.03 to $2.47 over the next 12 months.
Balance Sheet: Stockholders' equity, the net worth of the company, has increased by 21.8% in the most recent quarter from the same quarter last year.
Stock Ratios: The company's 5-year annualized growth rate for sales of 9.9% exceeds the industry average contraction of 5.2% and the S&P 500 sales growth rate of 2.6%.
Our model rates Monro Muffler Brake at a grade of A-Plus, or strong buy. In total there are three analysts awarding the company a strong buy recommendation with two hold recommendations.
TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.